Eisai Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for EISAI INC, and what generic alternatives to EISAI INC drugs are available?
EISAI INC has eleven approved drugs.
There are fifteen US patents protecting EISAI INC drugs.
There are three hundred and twenty-seven patent family members on EISAI INC drugs in forty-three countries and thirty-nine supplementary protection certificates in eighteen countries.
Summary for Eisai Inc
International Patents: | 327 |
US Patents: | 15 |
Tradenames: | 8 |
Ingredients: | 7 |
NDAs: | 11 |
Drug Master File Entries: | 1 |
Drugs and US Patents for Eisai Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | 11,090,386*PED | ⤷ Free Trial | Y | ⤷ Free Trial | |||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | ⤷ Free Trial | ⤷ Free Trial | |||||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-001 | Feb 13, 2015 | RX | Yes | No | 7,253,286*PED | ⤷ Free Trial | Y | ⤷ Free Trial | |||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | ⤷ Free Trial | ⤷ Free Trial | |||||
Eisai Inc | LENVIMA | lenvatinib mesylate | CAPSULE;ORAL | 206947-002 | Feb 13, 2015 | RX | Yes | Yes | 7,253,286*PED | ⤷ Free Trial | Y | ⤷ Free Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Eisai Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Eisai Inc | BANZEL | rufinamide | TABLET;ORAL | 021911-003 | Nov 14, 2008 | 6,740,669*PED | ⤷ Free Trial |
Eisai Inc | ARICEPT | donepezil hydrochloride | TABLET;ORAL | 020690-002 | Nov 25, 1996 | 6,245,911 | ⤷ Free Trial |
Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-001 | Oct 18, 2004 | 7,727,552 | ⤷ Free Trial |
Eisai Inc | BANZEL | rufinamide | SUSPENSION;ORAL | 201367-001 | Mar 3, 2011 | 7,750,028*PED | ⤷ Free Trial |
Eisai Inc | ARICEPT ODT | donepezil hydrochloride | TABLET, ORALLY DISINTEGRATING;ORAL | 021720-001 | Oct 18, 2004 | 4,895,841 | ⤷ Free Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for EISAI INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Capsules | 4 mg and 10 mg | ➤ Subscribe | 2019-02-13 |
➤ Subscribe | Tablets | 100 mg, 200 mg and 400 mg | ➤ Subscribe | 2012-11-14 |
➤ Subscribe | Orally Disintegrating Tablets | 5 mg and 10 mg | ➤ Subscribe | 2010-06-30 |
➤ Subscribe | Tablets | 23 mg | ➤ Subscribe | 2013-07-09 |
➤ Subscribe | Oral Suspension | 40 mg/mL | ➤ Subscribe | 2014-06-16 |
International Patents for Eisai Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Israel | 175933 | ⤷ Free Trial |
Australia | 2006203099 | ⤷ Free Trial |
World Intellectual Property Organization (WIPO) | 2016063995 | ⤷ Free Trial |
European Patent Office | 1830886 | ⤷ Free Trial |
Hong Kong | 1094200 | ⤷ Free Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Eisai Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1698623 | 261 5023-2015 | Slovakia | ⤷ Free Trial | PRODUCT NAME: LENVATINIB MESYLAT; REGISTRATION NO/DATE: EU/1/15/1002/001 - EU/1/15/1002/002 20150601 |
1415987 | 15C0070 | France | ⤷ Free Trial | PRODUCT NAME: LENVATINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI OU UN HYDRATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/15/1002 20150601 |
1087960 | 1190021-4 | Sweden | ⤷ Free Trial | PRODUCT NAME: ERIBULIN OCH FARMACEUTISKT ACCEPTABLA SALTER DAERAV, I SYNNERHET ERIBULINMESYLAT; REG:NO:/DATE: EG EU/1/11/678/001-002, 2011-03-17 |
1415987 | C01415987/01 | Switzerland | ⤷ Free Trial | PRODUCT NAME: LENVATINIB; REGISTRATION NO/DATE: SWISSMEDIC 65512 19.08.2015 |
1698623 | PA2015039,C1698623 | Lithuania | ⤷ Free Trial | PRODUCT NAME: LENVATINIBAS; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.